Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02871349 · ClinicalTrials.gov registry record · Early Phase 1
Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response
A Early Phase 1 study of Autism Spectrum Disorder, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 69
- Enrollment target
- 1
- Study location
NCT02871349 is a Early Phase 1 study of Autism Spectrum Disorder that has completed, run by University of Missouri-Columbia. The registered enrollment target is 69 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02871349, a Early Phase 1 study of Autism Spectrum Disorder, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out how the brain of people with autism is affected by Propranolol. Propranolol is not FDA approved for the treatment of autism. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure This research is being done because there are currently no drug treatment options for language impairments and social difficulties often experienced by people with autism.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Propranolol
- DEVICE Magnetic Resonance Imaging (MRI)
Study Locations (1)
Missouri
- Thompson Center for Autism & Neurodevelopmental Disorders - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2016-08 |
| Est. Completion | 2020-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02871349
The ClinicalTrials.gov registry entry for NCT02871349 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (49% lower). The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02871349 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT02871349 about?
NCT02871349 is a clinical study titled "Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response". The purpose of this study is to find out how the brain of people with autism is affected by Propranolol. Propranolol is not FDA approved for the treatment of autism. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure This research is being done because there ar...
What is the current status of trial NCT02871349?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 69 participants. The study started on 2016-08. Estimated completion is 2020-08.
What conditions does trial NCT02871349 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder.
What interventions are being tested in trial NCT02871349?
The interventions under investigation include: Placebo (DRUG), Propranolol (DRUG), Magnetic Resonance Imaging (MRI) (DEVICE).
Who is sponsoring clinical trial NCT02871349?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02871349 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design
RECRUITING · Early Phase 1
-
Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD
COMPLETED · Early Phase 1
-
Effects of Drugs on Responses to Brain and Emotional Processes
COMPLETED · Early Phase 1
-
Study of Neuroimaging Biomarkers of Social Cognition Deficits in Adolescents (Age 13-17) With Autism Spectrum Disorder and Effects of Gabapentin
COMPLETED · Early Phase 1
-
Cannabidiol (CBD) in Adults With ASD
RECRUITING · Phase 1
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.